Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2Phase 2/3 1Phase 1/2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

NIH 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 1Breast 1

Conditions

Ovarian Neoplasms 1Neoplasm Metastasis 1Genetic Diseases, Inborn 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Breast Neoplasms 1

Interventions

Specimen Handling 132Magnetic Resonance Spectroscopy 107Biopsy 79pembrolizumab 66Nivolumab 63Carboplatin 62Cisplatin 60Cyclophosphamide 56Paclitaxel 47Radiotherapy 37Gemcitabine 37Bevacizumab 36Dexamethasone 33Pemetrexed 28Rituximab 27Fluorouracil 27Doxorubicin 26olaparib 25Injections 25fludarabine 24durvalumab 24atezolizumab 24Radiation 24Ipilimumab 23Docetaxel 23Oxaliplatin 22Cytarabine 22venetoclax 21Vincristine 21Taxes 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Alpelisib × 30 days × Clear all
NCT05564377 2026-06-02

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

National Cancer Institute (NCI)

Phase 2 Recruiting
2,900 enrolled
Gynecologic

Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Endometrial Neoplasms

NCT05392608 2026-05-22

SEQUEL-Breast

Borstkanker Onderzoek Groep

Phase 2 Active not recruiting
130 enrolled
Breast

Breast Neoplasms, Genetic Diseases, Inborn

Data powered by HemOnc (CC BY 4.0) Colophon âš¡